IPO for Adial Pharmaceuticals, Inc.

$9.00–11.00 (Est. Date 12/20/2017)

Sign up to place a conditional IPO order

Adial Pharmaceuticals, Inc. (the “company”) is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD”) using a lead investigational new drug product, AD04, a selective serotonin-3 antagonist (i.e., a “5-HT3 antagonist”). The active ingredient in AD04 is ondansetron, which is also the active ingredient in Zofran®, an approved drug for treating nausea and emesis. AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption. The Company intends to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes. The Company believes the approach is unique in that it targets the serotonin system and individualizes the treatment of AUD, through the use of genetic screening. The Company has created an investigational companion diagnostic biomarker test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), the company believes will benefit from treatment with AD04. The Company’s strategy is to integrate the pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. The Company’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.

Show More
This information has been gathered from the company's offering prospectus.

IPO Documentation

Loading...

Key IPO Data

ADIL
NASDAQ
14,000,000
1,400,000
Joseph Gunnar & Co.
This information has been gathered from the company's offering prospectus.

How Does an IPO Work?

Open a Motif Account

Open a brokerage account to get ready for trading.

Participate in an IPO

Review IPO pricing, prospectus, and other documentation.

Place a Conditional Order

Select an investment amount and fund the IPO.

Receive Your IPO Shares

View your allocated shares on account positions page.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.